Telesis Bio (NASDAQ:TBIO) reported quarterly losses of $(5.52) per share which missed the analyst consensus estimate of $(0.23) by 2300 percent. The company reported quarterly sales of $3.440 million which missed the analyst consensus estimate of $6.900 million by 50.14 percent. This is a 45.54 percent decrease over sales of $6.316 million the same period last year.
Telesis Bio Q1 2024 Adj EPS $(5.52) Misses $(0.23) Estimate, Sales $3.440M Miss $6.900M Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.